Physician profile
Mathew Samuel
NPI 1538178686
$1,814.13
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63.76 · 2020: $292 · 2021: $829 · 2022: $629.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $208.30 | 2020-2022 | |
| Esperion Therapeutics, INC. | $188.12 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.30 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.25 | 2020-2022 | |
| Novo Nordisk INC | $119.21 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $114.60 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $104.10 | 2020-2021 | |
| Amarin Pharma, INC. | $102.64 | 2019-2021 | |
| Vifor Pharma, INC. | $73.89 | 2020-2021 | |
| Astrazeneca Pharmaceuticals Lp | $62.32 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.50 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $55.50 | 2022 | |
| Endo Pharmaceuticals INC. | $46.68 | 2020-2021 | |
| Smith+Nephew, INC. | $32.81 | 2022 | |
| Janssen Scientific Affairs, LLC | $32.07 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $29.13 | 2020 | |
| Aurinia Pharma U.S., INC. | $27.95 | 2021 | |
| Abbvie INC. | $26.78 | 2021 | |
| Sunovion Pharmaceuticals INC. | $25.76 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.41 | 2022 | |
| Xeris Pharmaceuticals, INC. | $22.08 | 2022 | |
| Daiichi Sankyo INC. | $21.33 | 2022 | |
| Alexion Pharmaceuticals, INC. | $19.01 | 2022 | |
| Merck Sharp & Dohme LLC | $17.85 | 2021 | |
| Janssen Biotech, INC. | $16.00 | 2020 | |
| Glaxosmithkline, LLC. | $13.84 | 2019 | |
| Eisai INC. | $13.74 | 2021 | |
| Corcept Therapeutics | $12.65 | 2021 | |
| Lundbeck LLC | $11.31 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathew Samuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.